{"date":"2026-09-09","count":10,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6589-2026-09-09-2111-1xaa4nt","company_id":"6589","company":"台康生技","market":"上市","industry":"生技醫療","date":"2026-09-09","time":"21:11:01","subject":"本公司註銷庫藏股減資變更登記完成","clause":"第36款","fact_date":"2026-09-09","cite_as":"公開資訊觀測站重大訊息：台康生技（6589），2026-09-09 21:11，「本公司註銷庫藏股減資變更登記完成」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6589-2026-09-09-2110-p1h1y8","company_id":"6589","company":"台康生技","market":"上市","industry":"生技醫療","date":"2026-09-09","time":"21:10:48","subject":"本公司註銷限制員工權利新股減資變更登記完成","clause":"第36款","fact_date":"2026-09-09","cite_as":"公開資訊觀測站重大訊息：台康生技（6589），2026-09-09 21:10，「本公司註銷限制員工權利新股減資變更登記完成」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6876-2026-09-09-1611-18d6nck","company_id":"6876","company":"朗齊生醫*","market":"興櫃","industry":"生技醫療","date":"2026-09-09","time":"16:11:00","subject":"公告本公司董事會決議通過私募普通股補辦公開發行及申請登錄興櫃","clause":"第44款","fact_date":"2026-09-09","cite_as":"公開資訊觀測站重大訊息：朗齊生醫*（6876），2026-09-09 16:11，「公告本公司董事會決議通過私募普通股補辦公開發行及申請登錄興櫃」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4172-2026-09-09-1610-1v20vp9","company_id":"4172","company":"因華","market":"興櫃","industry":"生技醫療","date":"2026-09-09","time":"16:10:36","subject":"公告本公司董事會決議辦理現金增資發行新股案","clause":"第9款","fact_date":"2026-09-09","cite_as":"公開資訊觀測站重大訊息：因華（4172），2026-09-09 16:10，「公告本公司董事會決議辦理現金增資發行新股案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6827-2026-09-09-1541-7suna6","company_id":"6827","company":"巨生醫","market":"興櫃","industry":"生技醫療","date":"2026-09-09","time":"15:41:27","subject":"本公司新藥MPB-1523 MRI顯影劑-肝細胞癌向美國FDA申請進行第三期臨床試驗","clause":"第8款","fact_date":"2026-09-09","cite_as":"公開資訊觀測站重大訊息：巨生醫（6827），2026-09-09 15:41，「本公司新藥MPB-1523 MRI顯影劑-肝細胞癌向美國FDA申請進行第三期臨床試驗」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6734-2026-09-09-1503-1op5qe1","company_id":"6734","company":"安盛生","market":"興櫃","industry":"生技醫療","date":"2026-09-09","time":"15:03:43","subject":"公告本公司董事會決議辦理115年第二次現金增資發行新股","clause":"第9款","fact_date":"2026-09-09","cite_as":"公開資訊觀測站重大訊息：安盛生（6734），2026-09-09 15:03，「公告本公司董事會決議辦理115年第二次現金增資發行新股」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6620-2026-09-09-1449-19wk8sa","company_id":"6620","company":"漢達","market":"上櫃","industry":"生技醫療","date":"2026-09-09","time":"14:49:25","subject":"本公司因近期股價價格異常，應櫃買中心要求公布相關資訊，俾便投資人暸解","clause":"第53款","fact_date":"2026-09-09","cite_as":"公開資訊觀測站重大訊息：漢達（6620），2026-09-09 14:49，「本公司因近期股價價格異常，應櫃買中心要求公布相關資訊，俾便投資人暸解」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4105-2026-09-09-1444-j5kfqh","company_id":"4105","company":"東洋","market":"上櫃","industry":"生技醫療","date":"2026-09-09","time":"14:44:24","subject":"本公司受邀參加國泰證券舉辦之線上法人說明會","clause":"第12款","fact_date":"2026-09-16","cite_as":"公開資訊觀測站重大訊息：東洋（4105），2026-09-09 14:44，「本公司受邀參加國泰證券舉辦之線上法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6472-2026-09-09-1443-1rqk7rk","company_id":"6472","company":"保瑞","market":"上市","industry":"生技醫療","date":"2026-09-09","time":"14:43:04","subject":"本公司受邀參加高盛證券舉辦之海外法人說明會","clause":"第12款","fact_date":"2026-09-23","cite_as":"公開資訊觀測站重大訊息：保瑞（6472），2026-09-09 14:43，「本公司受邀參加高盛證券舉辦之海外法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6917-2026-09-09-1023-1fqkmsr","company_id":"6917","company":"竟天","market":"興櫃","industry":"生技醫療","date":"2026-09-09","time":"10:23:29","subject":"澄清媒體報導","clause":"第26款","fact_date":"2026-09-09","cite_as":"公開資訊觀測站重大訊息：竟天（6917），2026-09-09 10:23，「澄清媒體報導」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}